Cicatricial pemphigoid with circulating autoantibodies to beta4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230
M. Leverkus(University of Würzburg), Detlef Zillikens(University of Lübeck), A. R. Ahmed(Nirma University), G. Baier(Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde), Hendri H. Pas(University Medical Center Groningen), Kailash C. Bhol(Avaxia Biologics (United States)), Y. Hirako(Nagoya University), M. F. Jonkman(University Medical Center Groningen), E.-B. Bröcker, Cassian Sitaru(University of Freiburg)
Cited by 68
Related Papers
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|597
Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
|New England Journal of Medicine|2006|452
Diagnosis and management of pemphigus: Recommendations of an international panel of experts
|Journal of the American Academy of Dermatology|2018|384
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
|Journal of the American Academy of Dermatology|2011|379
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
|Journal of the European Academy of Dermatology and Venereology|2020|332